Attention! Information is for reference only!
Before taking the course, consult a doctor!
WEB SITE ONLY DIRECTORY. NOT PHARMACY! We do not sell medicines! None!
0 1 2 3 4 5 6 7 8 A B C D E F G H I J K L M N O P Q R S T U V W X Y

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Description of the medicine: Buserelin (Buserelin)

BUSERELIN (Buserelin).

Synonym: Suprefact, Suprefakt.

Synthetic analogue of gonadotropin releasing factor.

Produced in the form of acetate (C 60 H 86 N 16 O 13 · C 2 H 4 O 2 ).

It binds (competitively) to the receptors of the anterior pituitary cells and blocks their gonadotropic function: inhibits the release of luteinizing and follicle-stimulating hormones, which leads to suppression of the synthesis of sex hormones in the ovaries and seminal vesicles.

Applied with endometriosis, uterine myoma, infertility, as well as hormone-dependent prostate gland.

Assign intranasally and subcutaneously.

When endometriosis is administered intranasal by 0.3 mg 3 times a day, starting on the 1st or 2nd day after the onset of menstruation; Duration of treatment up to 6 months.

When preparing for ovulation induction, subcutaneously, 0.2-0.5 mg once a day, or intranasal by 0.15-0.3 mg 4 times a day for 1-3 weeks (before the appointment of gonadotropin chorionic), starting with 1st or 21st day of the menstrual cycle.

In the treatment of infertility, the method of in vitro fertilization is administered intranasally by 0.15 mg 4 times a day, starting from the middle of the luteal phase of the menstrual cycle (21-24 days of the cycle) until the day of the administration of the ovulatory dose of chorionic gonadotropin.

When prostate cancer is administered subcutaneously to 6.6 mg (contents of the applicator) 1 time in 2 months.

Possible side effects: dyspepsia, impotence, gynecomastia, allergic reactions, mental disorders (anxiety, insomnia, memory and attention disturbance, depression), dizziness, increased blood pressure, dry mucous membranes and skin, impaired liver function, leukopenia, thrombocytopenia, violation Hearing.

The drug is contraindicated in pregnancy and lactation.

Form release: 0.3% solution for injection in vials of 1; 3 and 5.5 ml; 0.2% aerosol for intranasal use in vials of 8.5 and 17.5 ml; Implant in the form of 2 metered doses of 6.6 mg for subcutaneous administration.